Indaptus Therapeutics, Inc.
INDP
$0.2701
-$0.0589-17.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.83% | -7.33% | -2.49% | 2.36% | -5.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.81% | -6.18% | -5.60% | 5.71% | -0.61% |
| Operating Income | -0.81% | 6.18% | 5.60% | -5.71% | 0.61% |
| Income Before Tax | -5.15% | 2.60% | 1.21% | -7.71% | 1.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.15% | 2.60% | 1.21% | -7.71% | 1.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.15% | 2.60% | 1.21% | -7.71% | 1.54% |
| EBIT | -0.81% | 6.18% | 5.60% | -5.71% | 0.61% |
| EBITDA | -0.82% | 6.18% | 5.60% | -5.71% | 0.61% |
| EPS Basic | 16.20% | 11.67% | 4.51% | -6.28% | 2.82% |
| Normalized Basic EPS | 16.19% | 11.67% | 4.51% | -6.28% | 2.83% |
| EPS Diluted | 16.20% | 11.67% | 4.51% | -6.28% | 2.82% |
| Normalized Diluted EPS | 16.19% | 11.67% | 4.51% | -6.28% | 2.83% |
| Average Basic Shares Outstanding | 28.05% | 11.36% | 4.25% | 1.37% | 1.37% |
| Average Diluted Shares Outstanding | 28.05% | 11.36% | 4.25% | 1.37% | 1.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |